Tarsus Pharmaceuticals Inc. announced results from a pivotal trial of its therapy for Demodex blepharitis, which could lead to an FDA filing to treat the common eye disease for which there are no FDA-approved medications.

Lenz Therapeutics Inc. emerged from stealth mode with $47 million in series A financing to fund its mission to bring a drug therapy to bear on farsightedness, a problem that affects much of humanity, at one point or another.